HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2 ) VERSUS R PLUS PLACEBO

Autor:	Ian W. Flinn, A. Tabah, Stacey Kalambakas, John G. Gribben, Laura Fogliatto, Chengqing Wu, Adriana Scheliga, Cláudia Moreira, Antonello Pinto, Koji Izutsu, Nathan Fowler, John P. Leonard, M. Trněny, Huilai Zhang, Phillip Scheinberg, S. Abouzaid, G.S. Nowakowski, Fritz Offner, Xiaonan Hong, Pierre Fustier, Francesca Re
Rok vydání:	2019
Předmět:	Oncology Health related quality of life Cancer Research medicine.medical_specialty business.industry Hematology General Medicine Placebo Internal medicine Relapsed refractory Medicine Rituximab Augment business medicine.drug Lenalidomide
Zdroj:	Hematological Oncology. 37:232-234
ISSN:	0278-0232
DOI:	10.1002/hon.45_2630
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::276f5e329b880f1145768d396c5a731c https://doi.org/10.1002/hon.45_2630 Zobrazit plný text záznamu Plný text